SHANDON DIAGNOSTICS LIMITED

1. SHANDON DIAGNOSTICS LIMITED 2019-08-23 → present
2. THERMO SHANDON LIMITED 2000-11-29 → 2019-08-23
3. SHANDON SCIENTIFIC LIMITED 1998-01-05 → 2000-11-29
4. LIFE SCIENCES INTERNATIONAL (EUROPE) LIMITED 1993-03-01 → 1998-01-05
5. SHANDON SCIENTIFIC LIMITED 1988-05-03 → 1993-03-01
6. SHANDON SOUTHERN PRODUCTS LIMITED 1937-08-24 → 1988-05-03

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

KPMG LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have prepared the financial statements on the going concern basis as they do not intend to liquidate the Company or to cease its operations, and as they have concluded that the Company's financial position means that this is realistic They have also concluded that there are no material uncertainties that could have cast significant doubt over its ability to continue as a going concern for at least a year from the date of approval of the financial statements ("the going concern period").”

Group structure

1. SHANDON DIAGNOSTICS LIMITED · parent
   1. Epredia Belgium BV 100% · Belgaum · Manufacture of medical instruments
   2. Epredia Hong Kong Limited 100% · Hong Kong · Manufacture of medical instruments
   3. Epredia Hungary KFT 100% · Hungary · Manufacture of medical instruments
   4. Epredia India Private Limited 99.9% · India · Dormant
   5. Epredia Italy S.R.L. 100% · Italy · Manufacture of medical instruments
   6. Shandon Diagnostic Sdn Bhd. 100% · Malaysia · Dormant
   7. Epredia Netherlands B.V. 100% · Netherlands · Manufacture of medical instruments
   8. Epredia Singapore Pte Ltd 100% · Singapore · Manufacture of medical instruments
   9. Epredia Taiwan Limited 100% · Taiwan · Dormant

Significant events

• “The E1000 Dx Digital Pathology Solution (E1000 Dx) received clearance from the US Food and Drug Administration early March 2025 and that allows the company to start selling these instruments in the USA to the clinical market.”
• “The company's immediate parent company "Epredia Holdings Limited" has agreed to irrevocable and unconditionally release and discharge the loan balance amounting to £34,591,019 and trade payables balance of £8,265,979 as capital contribution and release the company from all its present and future obligations, liabilities arising in connection with the loan and trade payables balance.”
• “The company received a loan of £2.3 million on 15 May 2025 from Epredia Holdings Limited.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  0%

  £57,064,000 → £57,080,000

• Cash

  +31.1%

  £2,194,000 → £2,876,000

• Net assets

  +110.5%

  -£22,904,000 → £2,409,000

• Employees

  -4.7%

  232 → 221

• Operating profit

  +26.4%

  -£16,088,000 → -£11,836,000

• Profit before tax

  +24.2%

  -£19,584,000 → -£14,850,000

• Wages

  +1.9%

  £10,745,000 → £10,949,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers